# PTC Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ptc-therapeutics

- Industry: Biotechnology
- Headquarters: South Plainfield, US
- Website: www.ptcbio.com
- Total disclosed funding: $76M
- Latest round: Series E (Dec 22, 2009)
- Investors on record: 11

## About

PTC Therapeutics, Inc. is a biopharmaceutical company committed to developing innovative therapies for rare diseases, focusing on unmet medical needs through advanced research and development.Founded in 1998 in South Plainfield, New Jersey, PTC Therapeutics, Inc. specializes in biopharmaceuticals. The company has undergone significant funding rounds, including a PIPE in February 2014, raising USD 1,000 mn, backed by Blackstone Group. The company has executed a total of 18 funding deals since its inception.PTC Therapeutics offers a range of innovative therapeutics for rare diseases, including the first approved treatment for Duchenne muscular dystrophy and Sephience™ for phenylketonuria. Their products are available in the United States and Europe, targeting the needs of patients and healthcare providers managing chronic conditions.In 2024, PTC Therapeutics generated a revenue of USD 806.78 mn, with an EBITDA of USD -226.91 mn, primarily through direct sales of their proprietary products to healthcare providers and institutions.PTC Therapeutics plans to expand its product portfolio with upcoming releases targeting rare disease treatments. The company aims to enter new markets, particularly in Europe and Asia, by 2025. Recent funding from the PIPE will support these growth initiatives, providing resources for product development and market expansion.

## Funding rounds

- Series E, Dec 22, 2009, $50M — GCM Grosvenor, Delphi Ventures, HBM Partners, The Column Group, Celgene, Novo Holdings A/S
- Series E, Nov 10, 2005, $26M — GCM Grosvenor, Delphi Ventures, HealthCap, HBM Partners, Novartis Venture Fund, Amgen Ventures, Bay City Capital, Vulcan, Novo Holdings A/S

## Investors

- GCM Grosvenor — Series E
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series E
- HealthCap — Series E
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series E
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series E
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series E
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series E
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series E
- Novo Holdings A/S — Series E
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series E
- Celgene — Series E